Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Oral Decitabine in Relapsed/Refractory Acute Myeloid Leukemia
NCT04975919Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and inqovi in acute myeloid leukemia (AML) and Acute Biphenotypic Leukemia (BAL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate and Incidence of adverse events up to 2 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
venetoclaxinqovi
03
Conditions
acute myeloid leukemia (AML)Acute Biphenotypic Leukemia (BAL)
Beyond the preview
Go deeper on NCT04975919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975919.